Chemokine gene expression in the murine renal cell carcinoma, RENCA, following treatment in vivo with interferon-alpha and interleukin-2
Related Experiment Video
Updated: Aug 19, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
Published on: April 29, 2014
K Sonouchi1, T A Hamilton, C S Tannenbaum
1Department of Immunology, Cleveland Clinic Foundation, OH 46195.
Abstract:
The expression of three chemoattractant cytokine (chemokine) messenger (m)RNAs in the murine renal cell carcinoma (RENCA) from mice treated with a combination of interferon-alpha (IFN-alpha) and interleukin-2 was examined and related to tumor infiltration by inflammatory leukocytes. Using a semi-quantitative reverse transcriptase polymerase chain reaction assay, mRNAs encoding the KC, JE, and IP-10 genes were all elevated in tumor tissue from mice treated systemically with IFN-alpha/interleukin-2 for 4 days. Similarly, the mRNA for tumor necrosis factor-alpha (TNF-alpha) was also increased in tumors from treated as compared to control animals. The same tumors showed a significant increase in Mac-1+ leukocytes, which correlated well with the increase in chemokine and TNF-alpha gene expression. The renal cell carcinoma tumor itself may be responsible for the expression of chemokine genes in the tumor bed following cytokine therapy. Cultures of freshly explanted RENCA cells expressed significant levels of chemokine mRNAs when stimulated in vitro with IFN alpha, IFN gamma, and/or interleukin-2, demonstrating that this tumor cell has potential for expression of these genes in vivo. In contrast, TNF-alpha expression was not detected in cultured tumor cells. Thus TNF-alpha may be expressed by infiltrating monocytes following exposure to recombinant cytokine therapy.
Insights
Cytokine therapy with interferon-alpha and interleukin-2 increases chemokine gene expression in murine renal cell carcinoma (RENCA). This correlates with increased inflammatory leukocyte infiltration, suggesting RENCA cells may drive this response.
Area of Science:
- Immunology
- Cancer Biology
- Molecular Biology
Background:
- Cytokine therapy is investigated for cancer treatment.
- Interferon-alpha (IFN-alpha) and interleukin-2 (IL-2) are key immunomodulatory cytokines.
- Chemokines play a role in leukocyte recruitment to tumors.
Purpose of the Study:
- To examine chemokine mRNA expression in murine renal cell carcinoma (RENCA) after IFN-alpha/IL-2 treatment.
- To correlate chemokine expression with inflammatory leukocyte infiltration.
- To investigate the source of chemokine expression in the tumor microenvironment.
Main Methods:
- Semi-quantitative reverse transcriptase polymerase chain reaction (RT-PCR) assay.
- Analysis of murine RENCA tumors from treated and control mice.
- In vitro stimulation of cultured RENCA cells with cytokines.
Main Results:
- IFN-alpha/IL-2 treatment significantly elevated mRNA levels for chemokines KC, JE, and IP-10 in RENCA tumors.
- Tumor necrosis factor-alpha (TNF-alpha) mRNA also increased in treated tumors.
- Increased expression of Mac-1+ leukocytes correlated with elevated chemokine and TNF-alpha mRNA.
Conclusions:
- RENCA cells can express chemokine mRNAs in response to IFN-alpha, IFN-gamma, and IL-2 in vitro.
- Cytokine therapy may induce chemokine expression within the tumor bed.
- TNF-alpha may be expressed by infiltrating monocytes rather than tumor cells.
More Related Videos
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
05:36Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020